S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib
S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib
About this item
Full title
Author / Creator
Publisher
Basel, Switzerland: Cell Physiol Biochem Press GmbH & Co KG
Journal title
Language
English
Formats
Publication information
Publisher
Basel, Switzerland: Cell Physiol Biochem Press GmbH & Co KG
Subjects
More information
Scope and Contents
Contents
Abstract
Background/Aims: Anaplastic thyroid cancer (ATC), with 25% BRAFV600E mutation, is one of the most lethal human malignancies that currently has no effective therapy. Vemurafenib, a BRAFV600E inhibitor, has shown promise in clinical trials, including ATC patients, but is being hampered by the acquisition of drug resistance. Therefore, com...
Alternative Titles
Full title
S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_crossref_primary_10_1159_000493296
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_crossref_primary_10_1159_000493296
Other Identifiers
ISSN
1015-8987
E-ISSN
1421-9778
DOI
10.1159/000493296
